Evidence map›Paper›PMID 39791180›Full record

ReviewEndocrine, metabolic & immune disorders drug targets2025

Gut Microbiota and Diabetes: Pioneering New Treatment Frontiers.

Rupendra Shakya, Ponnurengam Malliappan Sivakumar, Pranav Kumar Prabhakar

Abstract readReview
In one paragraph

Review in Endocrine, metabolic & immune disorders drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Metabolic Disease Management through Natural Products: A Thorough Exploration.Endocrine, metabolic & immune disorders drug targets · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rupendra ShakyaDepartment of Medical Laboratory Sciences, School of Allied Medical Sciences, Lovely Professional University, Panjab, 144001, India.
Ponnurengam Malliappan SivakumarSchool of Medicine and Pharmacy, Duy Tan University, Da Nang, Vietnam.
Pranav Kumar PrabhakarDepartment of Medical Laboratory Sciences, School of Allied Medical Sciences, Lovely Professional University, Panjab, 144001, India.ORCID 0000-0001-8130-1822

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes Mellitus (DM) is a complex metabolic disorder characterized by chronic hyperglycemia and poses significant global health challenges. Conventional treatments, such as insulin therapy and lifestyle modifications, have shown limited efficacy in addressing the multifactorial nature of DM. Emerging evidence suggests that gut microbiota, a diverse community of microorganisms critical for metabolism and immune function, plays a pivotal role in metabolic health. Dysbiosis, an imbalance in gut microbiota composition, has been linked to insulin resistance, obesity, and DM. Gut microbiota influences glucose metabolism through mechanisms, including short-chain fatty acid production, gut permeability regulation, and immune system interactions, indicating a bidirectional relationship between microbial health and metabolism. Clinical and experimental studies demonstrate that modulating gut microbiota through dietary interventions (prebiotics, probiotics, synbiotics) improves glycemic control and insulin sensitivity in DM patients. Fecal Microbiota Transplantation (FMT) has also shown promise in restoring healthy gut microbiota and alleviating DM-related metabolic disturbances. However, challenges remain, including the need for personalized treatments due to individual microbiota variability and the unknown long-term effects of these interventions. Future research should focus on elucidating the mechanisms by which gut microbiota influences metabolism and refining personalized approaches to enhance DM management.

Indexed as

Diabetes MellitusFecal Microbiota TransplantationGastrointestinal MicrobiomeAnimalsBlood GlucoseDysbiosisHumansInsulin ResistancePrebioticsProbioticsBlood GlucosePrebioticsdysbiosisglycemic controlGut microbiotaprebioticsprobioticssymbiotic.

Identifiers

PMID39791180
PMCPMC12376105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.